According to the Zhicheng Caijing APP, Igaming-B (01541) rose more than 20% in intraday trading, and as of press time, it increased by 12.4%, to HK $14.5, with a turnover of 6.1465 million HK dollars.

On the news front, Yiming Augengke announced that on July 1, 2024, the company successfully completed the first patient dosing in a phase III clinical trial for classical Hodgkin's lymphoma (cHL) patients with relapsed or refractory (R/R) after treatment with IMM01 (Tidapizumab) and Torerelimab monoclonal antibody combined with programmatic cell death protein 1 (PD-1) inhibitor.

In addition, at the end of last month, the company announced that it has obtained a new drug clinical trial license for the Ib/III phase clinical trial of IMC-002 for the treatment of optic spinal spectrum diseases approved by the Chinese National Medical Products Administration. IMC-002 independently developed by the Group, is a bispecific molecule that targets differentiation clusters 47 and differentiation clusters 20, and can simultaneously bind to CD47 and CD20 expressed on malignant B cells through enhanced antibody-dependent cell phagocytosis and antibody-dependent cell cytotoxicity.